Noom's Two-Track GLP-1 Strategy

Noom Med shows that Noom is no longer just selling coaching, it is building a full weight loss checkout that can catch patients whether they want the cheapest monthly option or an FDA approved branded drug. In practice that means one path uses compounded semaglutide at an entry price of $149, while the other routes eligible patients to branded Zepbound vials through LillyDirect’s pharmacy partner Gifthealth inside the same app and care flow.1 2 3 4 5

• The two tracks solve two different customer problems. Compounded GLP-1s lower the starting cash cost for people paying out of pocket, while the LillyDirect integration gives Noom a cleaner on label path for patients who want branded tirzepatide and a more durable supply route as compounding rules tighten.2 3 4 5
• This matters because Noom’s core business was already a large consumer weight loss funnel, estimated at $1B revenue in 2023. Adding prescribing lets Noom monetize the same user at a much higher lifetime value, because GLP-1 care involves recurring medication, dose changes, and ongoing coaching rather than a short diet subscription alone.1 6
• Competitively, Noom is choosing specialization over the broader telehealth bundle used by Ro and Hims & Hers. Its pitch is that drugs work better when paired with food logging, habit coaching, and taper off support inside one obesity focused workflow, rather than being one SKU inside a wider online pharmacy storefront.1 6 7

The next step is a market where branded GLP-1 access gets more normalized and price pressure rises on compounded offers. That favors platforms like Noom that can keep patients inside a broader behavior change program, because medication access becomes easier to copy but sustained weight loss support is harder to commoditize.1 2 3 4 6 7